There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AngioDynamics (ANGO), Ocuphire Pharma (OCUP) and Bluebird Bio (BLUE) with bullish sentiments.
AngioDynamics (ANGO)
In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on AngioDynamics. The company’s shares closed last Friday at $21.12, close to its 52-week high of $23.40.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 15.9% and a 72.0% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Edwards Lifesciences.
AngioDynamics has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.
See today’s analyst top recommended stocks >>
Ocuphire Pharma (OCUP)
Ocuphire Pharma received a Buy rating and a $20.00 price target from JonesTrading analyst Prakhar Agrawal today. The company’s shares closed last Friday at $5.84.
According to TipRanks.com, Agrawal is a 1-star analyst with an average return of -5.4% and a 18.2% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Phathom Pharmaceuticals, and Aldeyra Therapeutics.
Currently, the analyst consensus on Ocuphire Pharma is a Moderate Buy with an average price target of $20.00, which is a 232.2% upside from current levels. In a report issued on March 15, Cantor Fitzgerald also maintained a Buy rating on the stock with a $20.00 price target.
Bluebird Bio (BLUE)
Leerink Partners analyst Mani Foroohar maintained a Buy rating on Bluebird Bio today and set a price target of $72.00. The company’s shares closed last Friday at $29.98, close to its 52-week low of $24.24.
According to TipRanks.com, Foroohar is a 2-star analyst with an average return of 0.3% and a 49.1% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Rocket Pharmaceuticals, and Intellia Therapeutics.
Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $44.75, implying a 49.0% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $70.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
